These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 30472087)

  • 1. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
    Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
    EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
    Jin J; Li X; Guo W; Li F; Huang J; Huang X; Pan J; Huang S; Ye W; Ling Q; Jin J
    Oncol Rep; 2020 Jul; 44(1):273-282. PubMed ID: 32626988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.
    Lu Y; Jiang X; Li Y; Li F; Zhao M; Lin Y; Jin L; Zhuang H; Li S; Ye P; Pei R; Jin J; Jiang L
    J Transl Med; 2024 Sep; 22(1):867. PubMed ID: 39334157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
    Wang L; Cai W; Zhang W; Chen X; Dong W; Tang D; Zhang Y; Ji C; Zhang M
    Oncotarget; 2015 Sep; 6(29):27490-504. PubMed ID: 26314963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia.
    Pashaiefar H; Yaghmaie M; Tavakkoly-Bazzaz J; Ghaffari SH; Alimoghaddam K; Momeny M; Izadi P; Izadifard M; Kasaeian A; Ghavamzadeh A
    Genet Test Mol Biomarkers; 2018 Jun; 22(6):343-349. PubMed ID: 29812960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
    Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
    J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
    Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
    Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.
    Dellomo AJ; Baer MR; Rassool FV
    Cancer Lett; 2019 Jul; 454():171-178. PubMed ID: 30953707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
    Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
    Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide CRISPR screening identifies critical role of phosphatase and tensin homologous (
    Lin L; Tao J; Meng Y; Gan Y; He X; Li S; Zhang J; Gao F; Xin D; Wang L; Fan Y; Chen B; Lu Z; Xu Y
    J Zhejiang Univ Sci B; 2024 Aug; 25(8):700-710. PubMed ID: 39155782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Leuk Lymphoma; 2014 Jan; 55(1):110-20. PubMed ID: 23647058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells.
    Ryu H; Choi HK; Kim HJ; Kim AY; Song JY; Hwang SG; Kim JS; Kim DU; Kim EH; Kim J; Ahn J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
    Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
    Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.